Tanimilast

Star0

DB12800InvestigationalSmall molecule

CHF6001 has been used in trials studying the treatment of Asthma and Chronic Obstructive Pulmonary Disease.

Mechanism: Pharmacologically active on Phosphodiesterase 4
Curator reviewed
Formula / weight: C₃₀H₃₀Cl₂F₂N₂O₈S · 687.53 g/mol (avg)
Code names: CHF-6001 · J3.309.618F

Resolves to

Compound

UNII0984EU6E2FCAS1239278-59-1ChEMBLCHEMBL3113974PubChem70662473

Structure

InChIKeyVCFBPAOSTLMYIV-SANMLTNESA-NSMILESCS(=O)(=O)NC1=CC=C(C=C1OCC1CC1)C(=O)O[C@@H](CC1=C(Cl)C=[N+]([O-])C=C1Cl)C1=CC=C(OC(F)F)C(OCC2CC2)=C1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which companies are running trials of Tanimilast, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account